In patients with type 2 diabetes, once-weekly semaglutide significantly improved beta-cell function and glycaemic control compared to placebo, enhancing both insulin secretion and reducing fasting and postprandial glucose levels, though it was associated with mild gastrointestinal side effects.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
CATEGORIES
© -2025 hormoneinsightc . all rights reserve.